Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers
Treatment
Cancer Discovery
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
ESMO Open
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study
Nature Medicine
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Cell Reports Medicine
Clinical development and management of adverse events associated with FGFR inhibitors
Cancer Discovery
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
Clinical Cancer Research
Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Clinical Lung Cancer
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
Cancer Discovery
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Journal of Comparative Effectiveness Research
For what it’s worth: the complex area of medicine value assessment